No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 0.1367
- +0.0043+3.25%
Close Apr 26 16:00 ET
- 0.1368
- +0.0001+0.07%
Post 16:22 ET
5.93MMarket Cap-273P/E (TTM)
0.1464High0.1211Low437.88KVolume0.1230Open0.1324Pre Close59.93KTurnover1.74%Turnover RatioLossP/E (Static)43.39MShares1.530052wk High-1.38P/B3.44MFloat Cap0.113052wk Low--Dividend TTM25.16MShs Float7.3500Historical High--Div YieldTTM19.11%Amplitude0.1130Historical Low0.1360Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NLS Pharmaceutics Challenges Nasdaq Delisting
Express News | NLS Pharmaceutics Announces Receipt of Staff Delisting Determination From Nasdaq; Intends to Request Hearing
NLS Pharmaceutics Ltd Strategizes for Growth
Board Member Resigns From NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. Announces New Warrant Issue
XTL Biopharmaceuticals XTLB Term Sheet; NLS Pharmaceutics NLSP Offering and Licensing Deal
Comments
$NLS Pharmaceutics(NLSP.US$
NEWS
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
NEWS
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
$NLS Pharmaceutics(NLSP.US$ NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
5
4
$NLS Pharmaceutics(NLSP.US$ NLS Pharmaceutics Extends Loan Maturity Date
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg